Pragmatic Trial of COVID Vaccine Text Outreach Interventions
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 19,554
- 试验地点
- 2
- 主要终点
- Dose 1 Completion
研究概览
简要总结
This project aims to evaluate different approaches to increase COVID-19 vaccine uptake among at-risk patients at Penn Medicine in an equitable and systematic manner through a centralized outreach program. The investigators will evaluate different text-based scheduling and messaging approaches informed by behavioral science to increase uptake among eligible patients, including the use of clinician endorsement, opt-out framing, and scarcity.
详细描述
This project will evaluate a centralized approach to increasing COVID through direct outreach to eligible patients via text messaging. This pragmatic randomized controlled trial has the following aims:
Aim 1: To conduct systematic large scale text message outreach for vaccine delivery among a defined group of Penn Medicine in a way that advances equity.
Aim 2: To offer different scheduling workflows through text messaging that might increase uptake and reduce disparities.
Aim 3: To compare the equity and efficiency of different messages informed by behavioral science, including PCP endorsement, opt-out framing, and scarcity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Health Services Research
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients of Penn Medicine aged 18+ who reside in Philadelphia and who have had at least 1 visit in the past 5 years with a Penn Medicine primary care provider (PCP)
排除标准
- •Patients who have completed any dose of the vaccine at Penn Medicine, are currently scheduled to receive the vaccine, have externally documented vaccination records, or have previously received text-message based vaccine outreach.
结局指标
主要结局
Dose 1 Completion
时间窗: 1 month
Percentage of patients who complete the first dose of the COVID vaccine within 1 month of initial outreach
次要结局
- Vaccine Completion(2 months)
- Dose 1 Completion(2 months)
研究者
Shivan J Mehta
Principal Investigator
University of Pennsylvania